Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling.

Receptor for advanced glycation end products (RAGE) and its ligands are overexpressed in multiple cancers. RAGE has been implicated in tumorigenesis and metastasis, but little is known of the mechanisms involved. In this study, we define a specific functional role for an alternate splice variant termed RAGE splice variant 1 (RAGEv1), which encodes a soluble endogenous form of the receptor that inhibits tumorigenesis. RAGEv1 was downregulated in lung, prostate, and brain tumors relative to control matched tissues. Overexpressing RAGEv1 in tumor cells altered RAGE ligand stimulation of several novel classes of genes that are critical in tumorigenesis and metastasis. Additionally, RAGEv1 inhibited tumor formation, cell invasion, and angiogenesis induced by RAGE ligand signaling. Analysis of signal transduction pathways underlying these effects revealed marked suppression of c-jun-NH(2)-kinase (JNK) pathway signaling, and JNK inhibition suppressed signaling through the RAGE pathway. Tumors expressing RAGEv1 were significantly smaller than wild-type tumors and displayed prominently reduced activation of JNK. Our results identify RAGEv1 as a novel suppressor, the study of which may offer new cancer therapeutic directions.

[1]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[2]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[3]  H. Gaylord,et al.  AMERICAN ASSOCIATION FOR CANCER RESEARCH. , 1913, California state journal of medicine.

[4]  Y. Kubota,et al.  Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development , 2005, The Prostate.

[5]  Bert Grobben,et al.  Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion , 2002, Cell and Tissue Research.

[6]  S. Kondo,et al.  Induction of Receptor for Advanced Glycation End Products by EBV Latent Membrane Protein 1 and Its Correlation with Angiogenesis and Cervical Lymph Node Metastasis in Nasopharyngeal Carcinoma , 2008, Clinical Cancer Research.

[7]  T. Arumugam,et al.  RAGE and RAGE ligands in cancer. , 2007, Current molecular medicine.

[8]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[9]  H. J. Yoo,et al.  Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. , 2009, International journal of cardiology.

[10]  C. Heizmann,et al.  Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. , 2003, Biochemical and biophysical research communications.

[11]  Tadaaki Kirita,et al.  The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma , 2007, Virchows Archiv.

[12]  R. Harpio,et al.  S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. , 2004, Clinical biochemistry.

[13]  HidenoriKoyama,et al.  Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease , 2007 .

[14]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[15]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[16]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  H. Yokozaki,et al.  Expression of receptors for advanced glycation end‐products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer , 2002, The Journal of pathology.

[18]  Herbert J Zeh,et al.  Journal of Translational Medicine BioMed Central Review , 2009 .

[19]  H. Kaneto,et al.  Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.

[20]  T. Sasahira,et al.  Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas , 2005, Virchows Archiv.

[21]  田中 伸茂.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB,and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells , 2001 .

[22]  F. Santilli,et al.  Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. , 2007, Free radical biology & medicine.

[23]  R. Ramasamy,et al.  Mechanisms of Disease: advanced glycation end-products and their receptor in inflammation and diabetes complications , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[24]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[25]  D. Mayer,et al.  S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. , 2006, Experimental cell research.

[26]  A. Schmidt,et al.  RAGE: a novel biological and genetic marker for vascular disease. , 2009, Clinical science.

[27]  B. Salh.  c-Jun N-terminal kinases as potential therapeutic targets , 2007, Expert opinion on therapeutic targets.

[28]  V. D’Agati,et al.  Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42* , 2008, Journal of Biological Chemistry.

[29]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[30]  T. Zima,et al.  Receptor for Advanced Glycation End Products (RAGE)—Soluble Form (sRAGE) and Gene Polymorphisms in Patients with Breast Cancer , 2007, Cancer investigation.

[31]  A. Khera,et al.  Association Between Circulating Soluble Receptor for Advanced Glycation End Products and Atherosclerosis , 2009, Diabetes Care.

[32]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[33]  A. Enk,et al.  RAGE signaling sustains inflammation and promotes tumor development , 2008, The Journal of experimental medicine.

[34]  J. Wang,et al.  Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. , 2010, Neoplasma.

[35]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[36]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[37]  C. Heizmann,et al.  Calcium-regulated intramembrane proteolysis of the RAGE receptor. , 2008, Biochemical and biophysical research communications.

[38]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[39]  H. Tse,et al.  Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes , 2007, Diabetologia.

[40]  C. Schalkwijk,et al.  Advanced Glycation End Products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and Argpyrimidine , 2005, Annals of the New York Academy of Sciences.

[41]  J. Massagué,et al.  Molecular basis of metastasis. , 2008, The New England journal of medicine.